BD Biosciences/CD45 FITC/Gly A PE/CD41a PerCP-Cy™5.5/333175,BD Biosciences,,BD Biosciences,bdbiosciences,+,,Array.Array.Array蚂蚁淘厂家直采.

产品名称：BD Biosciences/CD45 FITC/Gly A PE/CD41a PerCP-Cy™5.5/333175

产品编号：333175

市场价：¥0.00

场地：美国(厂家直采)

产品分类：蛋白类>多肽>多肽合成>

联系QQ：1570468124

电话号码：4000-520-616

邮箱： info@ebiomall.com

美元价：待定

品牌： BD Biosciences

公司：BD Biosciences,Inc.

公司分类：

商品介绍

Product DetailsRecommended AssayReferences

Description

BD Oncomark™ CD45 FITC/Anti–glycophorin A PE/CD41a PerCP-Cy5.5 is intended for in vitro flow cytometric immunophenotyping of the development in the erythroid, leucocytic, and megakaryocytic cell lineages in peripheral blood and bone marrow. Megakaryocytes co-express the platelet-specific glycoprotein gpIIb/IIIa (CD41a) and CD45 throughout their differentiation. In contrast, glycophorin A expression is present during erythroid cell development, with a gradual decrease in CD45 intensity during erythroid maturation. Using this approach, erythroid and lymphoid cells can be clearly distinguished based upon their antigenic expression. CD45/Anti–glycophorin A/CD41a assays are used in the diagnosis of hematologic disorders.

Specificity	Clone	Format	Isotype	Entrez Gene ID
CD45	2D1	FITC	IgG₁, κ
CD235a (Glycophorin A)	GA-R2 (HIR2)	PE	IgG_2b, κ
CD41a	HIP8	PerCP-Cy™5.5	IgG₁, κ	3674

Resources & Tools
SpectrumViewer	Download MSDS

Preparation and Storage

The antibody reagent is stable until the expiration date shown on the label when stored at 2° to 8°C. Do not use after the expiration date. Do not freeze the reagent or expose it to direct light during storage or incubation with cells. Keep the outside of the reagent vial dry.

Do not use the reagent if you observe any change in appearance. Precipitation or discoloration indicates instability or deterioration.

Protection of Laboratory Workers from Occupationally Acquired Infections–Second Edition; Approved Guideline. Villanova, PA: National Committee for Clinical Laboratory Standards; 2001. NCCLS document M29-A2.
Bain B, Catovsky D. Current concerns in haematology 2: classification of acute leukaemia. J Clin Pathol. 1990;43:882-887.
Bain BJ. Immunological markers in acute myeloid leukaemia. Leukaemia Diagnosis: A Guide to the FAB Classification. 1990:65-68.
Centers for Disease Control. Update: universal precautions for prevention of transmission of human immunodeficiency virus, hepatitis B virus, and other bloodborne pathogens in health-care settings. MMWR. 1988;37:377-388.
de Haas M, von dem Borne A. CD41/CD61 Workshop Panel report. In: Kishimoto T, Kikutani H, von dem Borne AEGK, et al, eds. Leucocyte Typing VI: White Cell Differentiation Antigens. 1997:643-645.
de Vries E, De Bruin-Versteeg S, Comans-Bitter WM, et al. Correction for erythroid cell contamination in microassay for immunophenotyping of neonatal lymphocytes. Arch Dis Child Fetal Neonatal Ed. 1999;80:226-229.
Feng R, Shimazaki C, Inaba T, et al. CD34⁺/CD41a⁺ cells best predict platelet recovery after autologous peripheral blood stem cell transplantation. Bone Marrow Transplant. 1998;21:1217-1222.
Gahmberg CG, Jokinen M, Andersson LC. Expression of the major sialoglycoprotein (glycophorin) on erythroid cells in human bone marrow. Blood. 1978;52:379-387.
Helleberg C, Knudsen H, Hansen PB, et al. CD34⁺ megakaryoblastic leukaemic cells are CD38^-, but CD61⁺ and glycophorin A⁺: improved criteria for diagnosis of AML-M7? Leukemia. 1997;11:830-834.
Jackson A. Basic phenotyping of lymphocytes: selection and testing of reagents and interpretation of data. Clin Immunol Newslett. 1990;10:43-55.
Jackson AL, Warner NL. Preparation, staining, and analysis by flow cytometry of peripheral blood leukocytes. In: Rose NR, Friedman H, Fahey JL, eds. Manual of Clinical Laboratory Immunology. 3rd ed. Washington, DC: American Society for Microbiology; 1986:226-235.
Jennings LK, Ashmun RA, Wang WC, Dockter ME. Analysis of human platelet glycoproteins IIb-IIIa and Glanzmann"s thrombasthenia in whole blood by flow cytometry. Blood. 1986;68:173-179.
Jokinen M, Ehnholm C, Väisänen-Rhen V, et al. Identification of the major human sialoglycoprotein from red cells, glycophorin A^M, as the receptor for Escherichia coli IH 11165 and characterization of the receptor site. Eur J Biochem. 1985;147:47-52.
Loken MR, Shah VO, Dattilio KL, Civin CI. Flow cytometric analysis of human bone marrow. I. Normal erythroid development. Blood. 1987;69:255-263.
Qiao X, Loudovaris M, Unverzagt K, et al. Immunocytochemistry and flow cytometry evaluation of human megakaryocytes in fresh samples and cultures of CD34+ cells. Cytometry. 1996;23(3):250-259.
Rogers CE, Bradley MS, Palsson BO, Koller MR. Flow cytometric analysis of human bone marrow perfusion cultures: erythroid development and relationship with burst-forming units-erythroid. Exp Hematol. 1996;24:597-604.
Rothe G, Schmitz G. Consensus protocol for the flow cytometric immunophenotyping of hematopoietic malignancies. Leukemia. 1996;10:877-895.
Schwinzer R. Cluster report: CD45/CD45R. In: Knapp W, Dörken B, Gilks WR, et al, eds. Leucocyte Typing IV: White Cell Differentiation Antigens. New York, NY: Oxford University Press Inc; 1989:628-634.
Stelzer GT, Marti G, Hurley A, McCoy P, Jr., Lovett EJ, Schwartz A. US-Canadian consensus recommendations on the immunophenotypic analysis of hematologic neoplasia by flow cytometry: standardization and validation of laboratory procedures. Cytometry. 1997;30:214-230.
Templeton TJ, Keister DB, Muratova O, Procter JL, Kaslow DC. Adherence of erythrocytes during exflagellation of plasmodium falciparum microgametes is dependent on erythrocyte surface sialic acid and glycophorins. J Exp Med. 1998;187:1599-1609.
von dem Borne AEGKr, Modderman PW, Admiraal LG, Nieuwenhuis HK. Platelet antibodies, the overall results. In: Knapp W, Dörken B, Gilks WR, et al, eds. Leucocyte Typing IV: White Cell Differentiation Antigens. New York, NY: Oxford University Press; 1989:951-977.
Wise GE, Oakford LX, Dzandu JK. Ultrastructure of a transmembrane glycoprotein, glycophorin A. Tissue & Cell. 1988;20:219-227.
Wybenga LE, Epand RF, Nir S, et al. Glycophorin as a receptor for sendai virus. Biochem. 1996;35:9513-9518.

品牌介绍

BD是世界上最大的生产和销售医疗设备、医疗系统和试剂的医疗技术公司之一。致力于提高全世界人类的健康水平。BD专注于改进药物治疗，提高传染性疾病诊断的质量和速度，推进新型药物和疫苗的研究与发现。公司于1897年在纽约成立，总部位于美国新泽西州的富兰克林湖，业务可分为BD医疗、BD诊断、BD生物科学三大类，生产销售包括医用耗材、实验室仪器、抗体、试剂、诊断等产品。

公司介绍

更多...

产品分类

更多...